Compugen Ltd. announced on May 13, 2025, key leadership transitions set to take effect in September 2025, following the Annual General Meeting. Dr. Anat Cohen-Dayag, the current President and Chief Executive Officer, will assume the newly created role of Executive Chair of the Board of Directors, subject to shareholder approval.
Dr. Eran Ophir, currently the Chief Scientific Officer, has been appointed President and Chief Executive Officer and will also join the Board of Directors, subject to shareholder approval. Paul Sekhri will step down as Chair of the Board of Directors.
Dr. Cohen-Dayag, who has led Compugen as President and CEO since 2010, will focus on corporate strategy, strategic collaborations, and investor relations in her new role. Dr. Ophir, with nearly a decade of experience at Compugen, has been central to building the company's immuno-oncology pipeline and corporate strategy, ensuring continuity in scientific and operational leadership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.